Most medical device companies grow by acquisition, not organically, Imagin Medical (IMEXF) has many liquidity options!!
Management Team
Done it before!!
Boston-based, experienced medical device management team that has done it before.
• Led by Jim Hutchens, founder of two medical device start-ups and executive at Boston Scientific and Smith & Nephew corporations
Patents
Exclusive license to three U.S. issued patents from Lawrence Livermore National Labs
• Collaborative Research Agreement gives Imagin right of first refusal for new IP
Summary
Imagin Medical is focused establishing a new standard of care in detecting cancer in minimally invasive surgeries where endoscopes are used.
• Initially targeting bladder cancer, plan to launch first product in 2Q19, expand to other minimally invasive surgeries (MIS)
• Patented, ultrasensitive imaging technology based on advanced optical design and light sensors
• Listed on the Canadian Securities Exchange (CSE) under the symbol “IME”, and the OTC Pink under the symbol “IMEXF”
$500M U.S. Market Segment
• Most expensive cancer to treat due to over 50% recurrence rate • 6th most prevalent cancer, 3rd most prevalent in men
• $4.0 billion spent annually on bladder cancer surveillance; 4M cystoscopies annually
• 75,000 new cases per year in U.S., 380,000 worldwide
The i/Blue Imaging System
• An advanced, ultrasensitive technology based on a combination of innovative optical design and light sensors. Expected to be 100x times more sensitive, dramatically improving the speed, quality and effectiveness of current systems. Works in conjunction with fluorescing imaging agents to deliver images far superior to conventional white light systems in far less time – 10 minutes vs. one hour
• Employs patented Simultaneous Acquisition of Differing Images that automatically blends white light and fluorescence images into one, putting the cancer in context within the bladder and freeing the surgeon from manually switching back and forth between different images to resect the cancer
Mitigated Development Risk:
Concept Proven, Working Prototype Completed, In-human Research Study Underway • Invented by Dr. Stavros Demos at Lawrence Livermore National Laboratory in California and concept validated at the University of California, Davis.
• Under Dr. Demos, final stage of development moved to Laboratory for Laser Energetics at the University of Rochester (UR). Collaborative Research Agreement in place and Dr. Demos continues to support Imagin’s development team.
• 10-patient research study currently underway (1Q18) at University of Rochester Medical Center to validate previous bench-testing results
Imagin Medical Overview
i/BLUE IMAGING SYSTEM™ BLADDER CANCER DETECTION
Today’s Standard of Care
• Endoscopes with White Light (Visible)
*90% of the market – today’s Gold Standard
*Highly effective if cancer protrudes above the bladder wall (See A below)
*Limitations – flat tumors often appear as normal tissue; difficult to see cancer cells along the margins (See B below)
• Endoscopes with White Light and Blue Filter with Fluorescing Contrast Agent
*Improves visibility of flat tumors and provides better view of the margins (See C below)
*Not practical due to the full hour it takes before the cancer becomes visible
* Requires the surgeon to switch back and forth between two separate images to resect the cancer o Blue image highlights the cancer but doesn’t show its precise location within the bladder
* White image that shows the full landscape of the bladder, but doesn’t highlight the cancer
Future Standard of Care - i/Blue Imaging System - Disruptive Technology
• “Sees” the cancer in less than 10 minutes vs. one hour; optics 100X more sensitive • Eliminates switching back and forth by automatically blending the “white” and “fluorescence” images into one, putting cancer in context and enabling the surgeon to better visualize and resect cancer
• Makes technology practical, not only for the O.R., but also for the physicians’ office, reducing healthcare costs
• Adaptable to other minimally invasive surgical procedures where endoscopes are used
Intellectual Property
Exclusive license to three U.S. issued patents from Lawrence Livermore National Labs • Collaborative Research Agreement gives Imagin right of first refusal for new IP
Management Team
Boston-based, experienced medical device management team that has done it before. • Led by Jim Hutchens, founder of two medical device start-ups and executive at Boston Scientific and Smith & Nephew corporations
Strong Acquisition Market
Most medical device companies grow by acquisition, not organically; company expects to have significant value and multiple liquidity options
